# Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

> **NCT01231659** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 72 (actual)

## Conditions studied

- Postmenopausal Women
- Locally Advanced Metastatic Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT01231659
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08-09
- **Primary completion:** 2012-11-20
- **Final completion:** 2017-04-30
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2021-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01231659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01231659, "Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01231659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*